Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02572687
Title A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

gastric adenocarcinoma

lung non-small cell carcinoma


Durvalumab + Ramucirumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU

No variant requirements are available.